Clinical Trial 48334

Phoenix, AZ 85013


The Ivy Brain Tumor Center at Barrow Neurological Institute, a nonprofit translational research program, is conducting a Phase 0/2 clinical trial  to evaluate the combination of two targeted therapies, abemaciclib (a CDK4/6 inhibitor) and LY3214996 (an ERK inhibitor), in patients with recurrent glioblastoma. It is the first time this newly-developed drug combination will be tested in brain tumor patients

The goal of this study is to confirm that both drugs are capable of crossing the blood-brain barrier. Patients with positive results may continue to receive treatment in a Phase 2 study arm. We will also confirm if the study drugs are hitting the molecular targets.

  • CDK4/6, or cyclin-dependent kinase 4 and 6, are two proteins found in cells that accelerate growth and division. Abemaciclib, a CDK4/6 inhibitor, has the ability to block these proteins and prevent tumor cells from dividing.  
  • ERK proteins transmit a signal from the surface of a cell to the nucleus that triggers cell division. LY3214996, an ERK1/2 inhibitor, is a small-molecule drug that can stop the signal and block cancer cell growth.  
  • Abemaciclib is FDA approved for the treatment of breast cancer. 

  • Be 18 years or older
  • Have had prior resection (surgical removal) of a histologically diagnosed WHO grade IV glioma
  • Have been treated with radiation and a chemotherapy drug called temozolomide
  • Have been told by a doctor that their tumor has recurred (come back) or has progressed (grown or changed)

Clinical trials are medical research studies designed to test the safety and/or effectiveness of new investigational drugs, devices, or treatments in humans. These studies are conducted worldwide for a range of conditions and illnesses. Learn more about clinical research and participating in a study at About Clinical Trials.